The Urothelial Carcinoma Cohort of the Destiny-PanTumor02 Trial: Efficacy and Safety of Trastuzumab Deruxtecan in Patients with Metastatic HER2-Expressing (IHC 3+) Solid Tumors
This Medudy course is a video tutorial for physicians on the topic “The Urothelial Carcinoma Cohort of the Destiny-PanTumor02 Trial: Efficacy and Safety of Trastuzumab Deruxtecan in Patients with Metastatic HER2-Expressing (IHC 3+) Solid Tumors.” Dr. Niklas Klümper, a senior physician in urology at the University Hospital of Bonn specializing in medical tumor therapy, summarizes the key findings of the […] in this video.